Page last updated: 2024-08-24

simendan and Diabetic Cardiomyopathies

simendan has been researched along with Diabetic Cardiomyopathies in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akhtar, M; Akhtar, MS; Ali, J; Ansari, SH; Hassan, Q; Najmi, AK; Pillai, KK	1

Other Studies

1 other study(ies) available for simendan and Diabetic Cardiomyopathies

Article	Year
Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy. Clinical and experimental hypertension (New York, N.Y. : 1993), 2016, Volume: 38, Issue:1 Topics: Animals; Apoptosis; C-Reactive Protein; Cardiotonic Agents; Caspase 3; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Glutathione Peroxidase; Hydrazones; Hypoglycemic Agents; Insulin; Male; Malondialdehyde; Oxidative Stress; Pyridazines; Ramipril; Rats; Rats, Wistar; Simendan; Superoxide Dismutase; Tumor Necrosis Factor-alpha	2016

Article

Year

Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy.

Clinical and experimental hypertension (New York, N.Y. : 1993), 2016, Volume: 38, Issue:1

Topics: Animals; Apoptosis; C-Reactive Protein; Cardiotonic Agents; Caspase 3; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Glutathione Peroxidase; Hydrazones; Hypoglycemic Agents; Insulin; Male; Malondialdehyde; Oxidative Stress; Pyridazines; Ramipril; Rats; Rats, Wistar; Simendan; Superoxide Dismutase; Tumor Necrosis Factor-alpha

2016